ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
Study enrolled 268 patients, exceeding target enrollment.
該研究招收了268名患者，超過了目標入組人數。
Largest interventional study ever to be conducted in pulmonary sarcoidosis.
有史以來對肺結節病進行的最大規模的介入研究。
Topline data are expected in the third quarter of 2025.
預計將在2025年第三季度公佈頂線數據。
SAN DIEGO, July 22, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has completed enrollment in its global pivotal Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease with limited treatment options. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025.
聖地亞哥，2024年7月22日（GLOBE NEWSWIRE）——從事利用其專有tRNA合成酶平台發現和開發同類首創藥物的臨床階段生物技術公司Atyr Pharma, Inc.（納斯達克股票代碼：ATYR）今天宣佈，它已經完成了對肺結節病患者主要候選治療藥物efzotimofid的全球關鍵性3期EFZO-FIT研究的入組，一種主要的間質性肺病，治療選擇有限。該研究在9個國家的85箇中心招收了268名患者，超過了目標入組人數。該研究的頭條數據預計將在2025年第三季度公佈。